Evaluation for NCI Surgery Branch Clinical Studies
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00001823|
Recruitment Status : Recruiting
First Posted : November 4, 1999
Last Update Posted : August 17, 2018
The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells back to the patient.
This study will allow patients to under screening and evaluation for participation in NCI Surgery Branch Protocols
Patients must meet the minimum eligibility criteria for an NCI surgery Branch Treatment Protocol
Patients will undergo testing and evaluations as required by the appropriate NCI Surgery Branch Treatment protocol
|Condition or disease|
|Synovial Cell Cancer Melanoma Colorectal Cancer Lung Cancer Bladder Cancer|
Potential research candidates undergo thorough screening including laboratory tests, scans, x-rays and review of pathology slides to determine initial eligibility for Surgery Branch research protocols.
To permit evaluation of patients referred to the NCI Surgery Branch in order to identify individuals who will be suitable candidates for Surgery Branch clinical research protocols.
To assess frequency of HLA type, gene specific mutations or expression of neo antigens in malignant tumors across the population of cancer patients undergoing screening for NCI Surgery Branch Protocols.
Collect results of screening tests for use on subsequent research protocol as baseline (e.g., pretreatment) values.
Patient suspected of having, or with biopsy proven malignant disease.
Patient, parent or guardian (if a minor), is able to provide informed consent.
Patients who are being evaluated for or treated on NCI Surgery Branch protocols.
Patients enrolled on this protocol will be evaluated by NCI Surgery Branch physicians to determine the individual's suitability for participation in a clinical research protocol. An accrual ceiling of 6000 patients has been set to meet the screening needs of the Surgery Branch.
|Study Type :||Observational|
|Estimated Enrollment :||6000 participants|
|Official Title:||Evaluation for NCI Surgery Branch Clinical Research Protocols|
|Study Start Date :||July 1, 1999|
- Individuals suitable for Surgery Branch clinical research protocols [ Time Frame: 20 Years ]Total number of patients who enroll on Surgery Branch clinical research protocols
- Frequency of HLA type and expression of neo antigens in malignant tumors [ Time Frame: 20 years ]Frequency of HLA type and expression of neo antigens in tissue and blood samples
- Results of screening tests for use on subsequent research protocol asbaseline (e.g., pretreatment) values [ Time Frame: 20 years ]Aggregate results of screening tests
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001823
|Contact: Margaret Shovlin, R.N.||(866) 820-4505||IRC@nih.gov|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact NCI/Surgery Branch Recruitment Center 866-820-4505 email@example.com|
|Principal Investigator:||Steven A Rosenberg, M.D.||National Cancer Institute (NCI)|